Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Curb Your Enthusiasm (for a Housing Recovery)

    In this Economics Weekly, Richard de Chazal examines the U.S. housing market and discusses its opportunities and challenges in the year ahead.

    Read more

  • William Blair Accelerates Investment in Biotech Equity Research and Equities Platform

    William Blair today announced a strategic investment in its equities platform, expanding resources across biotech equity research and institutional sales and trading to support long-term client demand driven by sustained innovation and increasingly complex institutional strategies.

    Read more

  • Food Delivery Expanding Access to Meals, Groceries, and More

    Subscriptions, bigger baskets, and higher frequency: the economics of delivery are shifting fast.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures